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Background: Extracorporeal cardiopulmonary resuscitation (ECPR) is being used increasingly in the emergency and
critical care field in Japan. A major complication of ECPR is bleeding; however, the optimal initial heparin dose and
activated coagulation time (ACT) remain unknown. The aim of this study was to assess the appropriateness of our
initial anticoagulation protocol.
Methods: We retrospectively evaluated the initial heparin dose, ACT value, and incidence of bleeding and
thrombotic complications in post-cardiopulmonary arrest patients who received a fixed, body weight-unadjusted
loading dose of unfractionated heparin (3000 U) prior to veno-arterial extracorporeal membrane oxygenator (ECMO)
between February 2011 and November 2013 at Mie University Hospital, Japan.
Results: ACT was evaluated within 3 h of initiation of 32 consecutive ECPR patients. The mean heparin dose per
body weight was 53.6 U/kg and the mean ACT was 231.3 s. In 17 patients, ACT exceeded 200 s. Three patients
experienced fatal bleeding in the chest wall within 24 h of receiving ECMO. The mean heparin dose per kilogram
body weight, mean initial ACT, and mean duration of cardiopulmonary resuscitation (CPR) did not statistically differ
between the patients who experienced fatal bleeding and those who did not.
Conclusions: Fixed-dose heparin of 3000-U bolus resulted in a mean heparin dose per kilogram body weight of
53.6 U/kg and an ACT of 231.3 s and experienced 3 out of 32 fatal bleedings. Further researches are warranted to
optimize anticoagulation protocol for ECPR patients.
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Veno-arterial extracorporeal membrane oxygenation
(ECMO) is being used increasingly for extracorporeal car-
diopulmonary resuscitation (ECPR) in Japan because it
provides higher survival rates and better neurological out-
comes [1, 2]. Despite the development of this new tech-
nique, bleeding remains a major complication associated
with ECPR. In patients receiving ECMO, anticoagulants
such as unfractionated heparin are frequently used. In pa-
tients starting respiratory ECMO, the Extracorporeal Life
Support Organization (ELSO) recommends 50–100 U/kg
of unfractionated heparin given as a bolus injection and a
target activated coagulation time (ACT) of 1.5 times the* Correspondence: iwaci1ta@clin.medic.mie-u.ac.jp
Emergency and Critical Care Center, Mie University Hospital, Edobashi 2-174,
Tsu, Mie, Japan
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creativecommons.org/publicdomain/zero/1.0/normal value [3]. Ideally, the heparin dose should be care-
fully adjusted by referencing both the patient’s body
weight and normal ACT value; however, in the emergency
setting, it is extremely difficult to obtain these values.
Therefore, for practical reasons, at our hospital, we de-
cided to use a fixed, body weight-unadjusted loading dose
of 3000 U of unfractionated heparin in all patients under-
going ECPR.
To our knowledge, no studies examining the optimal
initial heparin loading dose and ACT for veno-arterial
ECMO have been conducted. Therefore, we retrospect-
ively assessed the initial heparin loading protocol for
veno-arterial ECMO used at our hospital. To achieve
this objective, we firstly analysed the relationship be-
tween heparin dose and ACT value in our hospital by
comparing with ELSO’s recommendation. Secondly, wearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Comparison of anticoagulation protocols
Our protocol ELSO guideline
Initial dose 3000 Ua 50–100 U/kg
Additional dose 2000–5000 U NA
Target ACT 180–200 s 1.5 times the normal value
ACT activated coagulation time, ELSO Extracorporeal Life Support Organization,
NA not applicable
aFixed and body weight unadjusted
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period.
Methods
We retrospectively investigated patients who had experi-
enced cardiopulmonary arrest and in whom veno-
arterial ECMO was initiated at Mie University Hospital,
Japan, between February 2011 and November 2013. The
study protocol was approved by the institutional review
board of Mie University Hospital.
A CAPIOX (Terumo, Tokyo, Japan) ECMO system
with a heparin-coated pump and cannulae was used in
all of the study patients. A 12- to 18-Fr arterial cannula
and a 20-Fr venous cannula were used in adult patients.
Twelve- or fourteen-Fr cannulae were used in paediatric
patients (<15 years old).
Upon cardiopulmonary arrest, conventional cardiopul-
monary resuscitation (CPR) was initiated in all of the
study patients in accordance with the American Heart
Association Guidelines for CPR and ECC (2010) without
the use of any adjunct devices in either the pre-hospital
or hospital setting [4, 5]. Indications for introducing
ECMO were age less than 75 years and cardiac arrest
time less than 60 min, and ECMO was initiated when
requested by one of our Board of Emergency Medicine-
certified physicians. Percutaneous cannulation was per-
formed in the emergency room by using the Seldinger
technique.
All the patients underwent hypothermia therapy (target
body temp., 34 °C) for at least 24 h and were gradually
rewarmed. Normal blood pressure was maintained by
adjusting the flow of blood through the ECMO pump and
by minimizing the use of inotrope and vasopressor agents.
Intra-aortic balloon pumps were placed in patients with
low pulse pressures. Continuous renal replacement ther-
apy was initiated for all renal indications. Ventilator
settings used were “lung rest”; positive end-expiratory
pressure, 5–10 cm H2O; low respiratory rate (<12/min);
and FiO2 <60 %.
A fixed, body weight-unadjusted loading dose of
3000 U of unfractionated heparin was administered to
all the study patients, and unfractionated heparin was
used for anticoagulation therapy during ECMO. ACT
was evaluated by using a Hemochron microcoagulation
system (Technidyne, New Albany, USA). ACT and body
weight were determined upon admission to the intensive
care unit. In three patients, body weight could not be
determined due to the patient’s clinical status or death,
so body weight was estimated from their age according
to the Japanese Ministry of Health, Labour, and Welfare
guidelines.
We recorded patient age, sex, initial heparin dose, and
initial ACT value; incidence of bleeding or thrombotic
complications occurring within 24 h of ECMO initiation;and survival and neurological outcomes after hospital
discharge. Fatal bleeding was defined as any bleeding
that required surgical or trans-arterial embolization to
maintain hemodynamic stability; minor bleeding was de-
fined as any bleeding that did not require surgical inter-
vention. Thrombotic complications were assessed by
visually checking for circuit clotting. Neurological out-
comes were assessed by using the Cerebral Performance
Category scale.
Continuous variables are presented as mean (range),
and categorical variables are presented in the text as per-
centages. Continuous variables were compared between
groups by using the Student’s t test. Categorical variables
were compared by using the chi-square test. For all ana-
lyses, significance was defined as P < 0.05. All analyses
were performed with statistical software (Statistical
Package for the Social Sciences [SPSS] version 18; SPSS
Japan Inc., Tokyo, Japan).
Results
The anticoagulation protocol currently used in our hos-
pital is shown in Table 1. The ECMO circuit is primed
by using a fixed, body weight-unadjusted loading dose of
3000 U of heparin-infused normal saline. If cannulation
takes longer than usual, an additional dose of heparin is
administered. Two patients in the present study received
a total of 7500 U of heparin, and one patient received a
total of 5500 U of heparin. All other patients received
3000 U of heparin.
ECMO was initiated in 45 patients during the study
period (Fig. 1). In one patient, ECMO was initiated twice
during the same hospitalization. In all other patients,
ECMO was initiated once at each hospitalization. ACT
was not measured within 3 h of admission to the inten-
sive care unit in 13 patients so they were excluded from
the study. Table 2 shows the patient demographics. The
mean age was 60.4 years. Twenty-seven patients (84.3 %)
were male. Nine patients (37.5 %) experienced cardiac
arrest during hospitalization. The mean duration of con-
ventional CPR prior to the initiation of ECMO was
48.6 min. The mean initial heparin dose was 53.6 U/kg
body weight, and the mean initial ACT was 231.3 s.
Nine out of the thirty-two patients (28.1 %) survived
to discharge, six of whom had a good neurological out-
come (Cerebral Performance Category 1 or 2). The
Fig 1 Study overview. Extracorporeal membrane oxygenation
(ECMO) was initiated in 45 consecutive patients. Thirteen patients
were excluded from the study because activated coagulation time
(ACT) was not determined within 3 h of admission to the intensive
care unit. The remaining 24 patients were included in the
present study
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bral hypoxia, low cardiac output syndrome, and multiple
organ failure. Three patients experienced fatal bleeding
during ECMO (Table 3), two of whom died as a conse-
quence. The remaining patient underwent interventional
radiology to stop the haemorrhage but died due to low
cardiac output syndrome. Figure 2 shows computed
tomography scans of the three patients who experienced
fatal bleeding; thoracic, intra-thoracic, and mediastinal
bleeding can be seen. There were no significant differ-
ences in age (P = 0.33), sex (P = 0.84), mean initial
heparin dose (P = 0.42), mean initial ACT (P = 0.89), or
mean duration of conventional CPR (P = 0.18) between
the patients who experienced fatal bleeding and those
who did not (Table 3). No significant thrombotic com-
plications were observed.Table 2 Patient demographics
Number of patients 32
Mean age 60.4 (12–87)
Sex (male to female ratio) 27:5
Mean initial heparin dose (U/kg) 53.6 (31.6–115.2)
Mean initial ACT (s) 231.3 (103–359)
Mean duration of conventional CPR (min) 48.6 (4–106)
Survival 9
CPC 1 or 2 6Discussion
It is difficult to measure body weight prior to initiating
ECMO in the emergency setting, so at our hospital, we
decided to use a fixed, body weight-unadjusted loading
dose of heparin as anticoagulation therapy. Therefore,
all the patients received 3000 U of heparin; three pa-
tients received an additional dose of heparin. As a result,
the initial mean heparin dose per kilogram body weight
was 53.6 U/kg and ACT of 231.3 s, and experienced 3
out of 32 fatal bleedings. Although the ELSO guideline
recommends a heparin bolus injection of 50–100 U/kg,
there is no definitive evidence showing that this dose is
sufficient to minimize mortality or morbidity [3]. Indeed,
a recently published multicentre prospective trial did not
use a fixed anticoagulation protocol for starting ECPR
[1]. Furthermore, the ELSO guideline was originally
intended for respiratory ECMO, so the appropriate dose
of initial heparin for ECPR patients remains unknown.
According to the ELSO database, the currently recom-
mended ACT value, 150–180 s, resulted in a rate of
bleeding complications of 30–35 %; however, these data
were obtained in the respiratory ECMO patients only
and more than 50 % of these patients were veno-
venously cannulated [6]. Patients who undertake percu-
taneous coronary intervention (PCI) are recommended
to receive 70–100 U/kg of unfractionated heparin and
resultant ACT of >250 s before PCI [7]. One of the rea-
sons that ECMO patients require a lower dose of hep-
arin with a shorter ACT value may be due to patient’
disease state. Indeed, in PCI patients, the severity of dis-
ease state is correlated with the incidence of post PCI
bleeding [8]. Patients who need ECMO are usually critic-
ally ill with deteriorated coagulation status. Therefore, a
study specifically examining anticoagulation strategy for
ECPR patients is needed.
Postcardiotomy patients receiving veno-arterial ECMO
frequently experience bleeding complications. Rastan et al.
analysed 517 consecutive postcardiotomy cardiogenic-
shock patients who required extracorporeal circulation
and found that 300/517 (58.0 %) patients underwent
rethoracotomy for bleeding complications [9]. Further-
more, Doll et al. reported that 136/219 (63.5 %) postcar-
diotomy patients who had undergone ECMO experienced
severe mediastinal bleeding requiring rethoracotomy [10].
These data suggest that the underlying etiology and type
of cannulation may influence the rate of bleeding
complications.
Since post-cardiac arrest patients have better neuro-
logical outcomes when treated with induced hypothermia
[11, 12], induced hypothermia therapy is often initiated to-
gether with ECPR. In the present study, all the patients
underwent mild hypothermia therapy (target temp., 34 °C).
Hypothermia is associated with increased risk of bleeding
[13, 14]. Chest compression is also associated with bleeding






(n = 29) (n = 3)
Age (mean) 59.5 69.3 0.33
Sex (male) 25 2
Mean initial heparin dose (U/kg) 54.6 44.7 0.42
Mean initial ACT (s) 263.5 224.3 0.89
Mean duration of conventional
CPR (min)
51.9 67 0.18
ACT activated coagulation time, CPR cardiopulmonary resuscitation
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compression in patients in cardiac arrest is to push more
than 3 cm; however, chest compression exceeding 6 cm is
associated with a greater incidence of complications [15].
Therefore, vigorous chest compression should be avoided
in patients in whom ECPR will be introduced. Further-
more, compared with patients in acute respiratory failure
receiving respiratory ECMO, patients receiving ECPR, as
well as postcardiotomy patients, have a higher risk of
bleeding. An improved anticoagulation protocol is needed
for these high-risk patients.
There were three cases of fatal bleeding related to
chest compression among the patients examined in the
present study. The mean initial heparin dose, mean ini-
tial ACT value, and mean duration of conventional CPR
were not statistically associated with the incidence of
fatal bleeding during ECMO (Table 3). Details of the fac-
tors contributing to these thoracic bleedings cannot be
detected with this small-sized observational study; how-
ever, rib fractures can clearly be seen near the hematoma
sites on computed tomography scans, so it is likely that
chest compression was a contributing factor (Fig. 2).
However, postmortem CT study for conventional CPR
patients has shown that the incidence of rib fracture was
70 %, while hemothorax was seen in only 0.45 % in the
conventional CPR patients [16]. Since our patient group
experienced 3 out of 32 (9.3 %) fatal chest hematoma,Fig 2 Computed tomography scans showing intra-thoracic, thoracic, and me
the three patients in the present study who experienced fatal bleedingwe assume that chest hematoma is exacerbated by our
anticoagulation therapy for ECPR.
There are several reports indicating the safety of using
a heparin-free ECMO circuit. Muehrcke et al. reported
the details of 30 individual cases of heparin-free ECMO
use; bleeding complications were reported in 12/30
(40 %) patients and 6 cases of intracardiac clotting were
reported [17]. In a prospective analysis of 32 postcardiot-
omy patients receiving veno-arterial ECMO, Lamarche
et al. reported that 14 (43.8 %) patients required rethora-
cotomy and that 2 patients experienced intracardiac
thrombus [18]. Recently, there are several reports indi-
cating IABP patients can be managed safely without
heparin when used for postcardiotomy patients [19, 20].
Together, these results suggest that the use of heparin-
free circuits may lower the overall incidence of bleeding
complications in postcardiotomy patients receiving
ECMO.
Few studies have examined clotting events. However,
Rastan et al. examined the findings of 78 autopsies of
patients who had received ECMO. They reported
thromboembolic findings in a total of 46.2 % cases,
15.4 % of which were known prior to death, indicating
that clinically visible thromboembolic events occur
much less frequently than subclinical thromboembolic
events do [21]. In the present study, we did not examine
thrombotic complications in detail; circuit clotting was
only checked for by means of visual observation. It is,
however, important to carefully monitor patients receiv-
ing ECMO for potential subclinical thromboembolic
events.
The use of the anticoagulant nafamostat as an alterna-
tive to heparin is currently being investigated. Han et al.
described the usefulness of nafamostat for both cardiac
and respiratory ECMO; patients receiving nafamostat re-
ceived less red blood cells and fresh frozen plasma com-
pared with patients receiving heparin [22]. The incidence
of haemorrhage or thrombosis was also lower in the nafa-
mostat group. Further studies are needed to clarify how to
avoid fatal bleeding in patients receiving ECPR.diastinal bleeding, presumably caused by excessive chest compression, in
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Fixed-dose heparin of 3000-U bolus resulted in a mean
heparin dose per kilogram body weight of 53.6 U/kg and
an ACT of 231.3 s, and experienced 3 out of 32 fatal
bleedings. Further research is warranted to optimize ap-
propriate anticoagulation protocol for ECPR patients. At
this point, avoiding vigorous chest compression and re-
ducing anticoagulating agents are the possible interven-
tion to minimize bleeding complications safely.
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